Zeng Zhiqiang
Managing Partner @ Huagai Capital
Beijing, China
Zeng Zhiqiang is a managing director at Huagai Capital. Prior to this, he worked in Galaxy Securities, Boshi Fund, and served as president of Beijing Founder and Health Investment Co., Ltd., Managing Director of CITIC Industrial Fund. He engaged in the investment business for many years, in a secondary market investment has extensive experience.Zeng completed a bachelor's degree in Economics from Guanghua School of Management, Peking University, an MBA from Crummer School of Business, Rollins University, and an EMBA from Tsinghua University.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Zeng Zhiqiang invests in
Stages Zeng Zhiqiang invests in
Countries Zeng Zhiqiang invests in
Investment Focus
Industry
- Health Care 4 (100%)
- Biotechnology 2 (50%)
- Pharmaceutical 2 (50%)
- Medical 1 (25%)
- Therapeutics 1 (25%)
Stage
- Series C 3 (75%)
- Series B 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Qitan Technology
|
Developer of a genome sequencing technology. The company takes advantage of nanopores to sequence single nucleic acid molecules.Using innovative nanopore gene sequencing technology, it provides single-molecule sequencing capability with long reading length, real-time output of sequencing results, low single-running cost, small and convenientinstrument, and cost-effective gene sequencing solution without complicated library preparation. It can directly detect the apparent modification of nucleic acids and expand the application of gene sequencing technology in cutting-edge biological research and clinical medicine such as instant diagnosis, metagenomics, epigenetics, RNA and transcriptomics. | $100.2M / Series C / Dec 23, 2022 | |
GenFleet Therapeutics
|
GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize thebody's own immune system. | $78.7M / Series C / Dec 31, 2021 | |
Jinfang Pharmaceutical
|
Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies. | $77.1M / Series C / Dec 31, 2021 | |
GeneQuantum Healthcare
|
GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company that focuses on the research and development of innovative Bio-therapeutics.GeneQuantum was founded in August 2013 at Suzhou Industrial Park, and has built-up a world-class bio-conjugation technology platform, focusing on developing series of next generation anti-tumorAntibody-Drug-Conjugates (ADCs) with best-in-class potential. Securing this round of financing will significantly promote the development of current ADC candidates towards IND filling in both US and China, meanwhile further expanding the company's product pipeline. | $14.2M / Series B / May 07, 2019 |
Co-Investors
ABC International
2 deals together
Baidu Ventures
2 deals together
CDH Investments
2 deals together
Dyee Capital
2 deals together
Huimei Capital
2 deals together
Pan-Lin Capital
2 deals together
About Huagai Capital
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Huagai Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Lu Binghui
President & Co-Founder
|
|||
|
Meng Nan
Executive General Manager
|
|||
Wang Shaokun
Vice President
|
|||
Xiaolin Xu
Chairman & Co-founder
|
|||
|
Zeng Zhiqiang
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Zeng Zhiqiang invest in?
Zeng Zhiqiang invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series C and Series B stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Zeng Zhiqiang last invest?
The most recent investment recorded for Zeng Zhiqiang closed in Dec 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
